Reply To: Traders Market Weekly: FTX, Silvergate and SVB. A Pattern of Tech & ESG Irrational Exuberance


Eli Lilly (LLY 309.05, -3.49, -1.1%): announced that solanezumab did not slow the progression of cognitive decline due to Alzheimer’s disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the preclinical stage of AD